ArticleRadiology. Imaging cancer2025
Prospective Evaluation of Contrast-enhanced Mammography for Early Prediction of Pathologic Response after Neoadjuvant Therapy.
Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer.European radiology · 2026Article
- Contrast-enhanced mammography in the setting of neoadjuvant therapy from a multidisciplinary perspective.Insights into imaging · 2026Review
- Contrast-Enhanced Mammography vs. Breast MRI for Assessing Neoadjuvant Chemotherapy Response: A Prospective Clinical Comparison Study.Diagnostics (Basel, Switzerland) · 2026Article
- Contrast-enhanced Mammography for Early Prediction of Neoadjuvant Therapy Response in Breast Cancer.Radiology. Imaging cancer · 2025Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To assess whether changes in contrast-enhanced mammography (CEM)-derived lesion measurements after the first cycle of neoadjuvant therapy (NAT) can predict pathologic complete response (pCR) in individuals with breast cancer. Materials and Methods This prospective single-center pilot study enrolled consecutive participants with breast cancer treated with NAT who underwent CEM at baseline (May 2018 to December 2018). CEM was performed before and after the first cycle of NAT. Two breast radiologists independently evaluated the percentage change in the longest dimension of the lesion (CLD) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria at CEM. Multivariable logistic regression was used to identify independent predictors of pCR, and predictive performance was assessed using area under the receiver operating characteristic curve (AUC). Results Thirty-six participants (mean age ± SD, 48 years ± 10.3) were included; 11 (30.5%) participants achieved pCR. A CLD of at least 20.93% independently predicted pCR (odds ratio, 9.52; 95% CI: 1.34, 67.23;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.